加载中
NASDAQHealthcareBiotechnology
最新数据
US$10.20
−US$0.26 · -2.49%
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
收盘时
US$10.20
−US$0.26 · -2.49%
盘后
US$10.17
−US$0.03 · -0.29%
10月13日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
日内区间
当前US$10.20
52周区间
当前US$10.20
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
买入
估值
87
深度低估
情绪
50
多空交织
风险
38
中等风险
动量
61
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
日内区间
当前US$10.20
52周区间
当前US$10.20
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$15.00
上涨空间 47.06%报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM4575.39万0.06%777.48亿 USD0.19%US$276.7-0.43%
Vanguard Morningstar Total Stock Market ETFVTI4383.45万0.00%2.3万亿 USD0.03%US$381.32-0.07%
Vanguard Extended Market ETFVXF1694.55万0.02%954亿 USD0.05%US$232.54-0.42%
iShares Russell 2000 Growth ETFIWO1648.28万0.12%137.9亿 USD0.24%US$351.1-0.74%
State Street SPDR S&P Pharmaceuticals ETFXPH1284.51万2.74%4.69亿 USD0.35%US$62.10-2.98%
Fidelity Enhanced Small Cap ETFFESM1161.28万0.18%64.1亿 USD0.28%US$45.15-0.20%
Schwab U.S. Small-Cap ETFSCHA1011.32万0.05%217.13亿 USD0.03%US$32.56-0.31%
First Trust Small Cap Growth AlphaDEX FundFYC947.8万0.70%13.49亿 USD0.70%US$114.19-0.57%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOState Street SPDR S&P Pharmaceuticals ETFXPHFidelity Enhanced Small Cap ETFFESMSchwab U.S. Small-Cap ETFSCHAFirst Trust Small Cap Growth AlphaDEX FundFYCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
